Role of vitamin K2 in the development of hepatocellular carcinoma in women with viral cirrhosis of the liver

JAMA

Volumn 292, Issue 3, 2004, Pages 358-361

  Habu, Daiki ^a   Shiomi, Susumu ^a   Tamori, Akihiro ^a   Takeda, Tadashi ^a   Tanaka, Takashi ^a   Kubo, Shoji ^a   Nishiguchi, Shuhei ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ALPHA INTERFERON; BILIRUBIN; FARNOQUINONE; MENADIONE; MENAQUINONE; MENATETRENONE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; BILIRUBIN BLOOD LEVEL; CANCER PREVENTION; CANCER RISK; CELL GROWTH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; ENZYME ACTIVITY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; LIVER TUMOR; MIDDLE AGED; VIROLOGY; VIRUS HEPATITIS;

CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; VITAMIN K 2;

EID: 3142708765     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.3.358     Document Type: Article

References (17)

1. Shiomi S, Nishiguchi S, Kubo S, et al. Vitamin K2 (menatetrenone) for bone loss in patients with cirrhosis of the liver. Am J Gastroenterol. 2002;97:978-981.
2. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346:1051-1055.
3. International Union Against Cancer. TNM Classification of Malignant Tumors. Sobin LH, Wittekind Ch, eds. 5th ed. New York, NY: Wiley-Liss; 1997.
4. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.
5. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174-181.
6. Ikeda K, Saitoh S, Koide I, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47-53.
7. Sasaki I, Hashimoto S, Yoda M, et al. Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines. Biochem Biophys Res Commun. 1994;205:1305-1310.
8. Nishimaki J, Miyazawa K, Yamaguchi M, et al. Vitamin K2 induces apoptosis of a novel cell line established from a patients with myelodysplastic syndrome in blastic formation. Leukemia. 1999;13:1399-1405.
9. Takami A, Nakao S, Ontachi Y, et al. Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog. Int J Hematol. 1999;69:24-26.
10. Carr BI, Wang Z, Kar S, Wang M. Prothrombin inhibits hepatocyte DNA synthesis (DNA-S) and expression of the α5-integrin gene. Proc Am Assoc Cancer Res. 1995;36:266.
11. Kar S, Carr BI. Growth inhibition and protein tyrosine phosphorylation in MCF breast cancer cells by a novel K vitamin. J Cell Physiol. 2000;185:386-393.
12. Varnum BC, Young C, Elliott G, et al. Axl receptor tyrosine kinase stimulated by the vitamin K-dependent protein encoded by growth-arrest-specific gene 6. Nature. 1995;373:623-626.
13. Ohizumi H, Masuda Y, Nakajo S, et al. Geranyl-geraniol is a potent inducer of apoptosis in tumor cells. J Biochem. 1995;117:11-13.
14. Pere G, Enrique Q, Vicente A, et al. Compensated cirrhosis: natural history and prognostic factors. Hepatology. 1987;7:122-128.
15. Marco Z, Maria RC, Guulio M, et al. Prognostic indicators in compensated cirrhosis. Am J Gastroenterol. 1991;86:1508-1513.
16. Jerome G, Lawrence S, Anne MB, Olivier C, Renee EP, Raoul P. Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. J Hepatol. 2000;32:447-452.
17. Orimo H, Shiraki M, Tomita A, Morii H, Fujita T, Ohata M. Effects of menatetrenone on the bone and calcium metabolism in osteoporosis: a adouble-blind placebo-controlled study. J Bone Miner Metab. 1998;16:106-112.